Endocan as a potential biomarker of disease severity and exacerbations in COPD

dc.contributor.authorErdal İn
dc.contributor.authorMutlu Kuluöztürk
dc.contributor.authorTeyfik Turgut
dc.contributor.authorAyşegül Altıntop Geçkil
dc.contributor.authorNevin İlhan
dc.date.accessioned2022-12-19T12:42:03Z
dc.date.available2022-12-19T12:42:03Z
dc.date.issued2021en_US
dc.departmentMTÖ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: Endocan is a proteoglycan that is regarded as a novel marker of endothelial dysfunction. Endothelial dysfunction in pulmonary vascular bed is known to play an important role for the pathogenesis of COPD. Objective: This study aimed to determine serum endocan levels in patients with stable COPD and acute exacerbation of COPD (AECOPD) and to test the relationship between serum endocan levels and exacerbations. Methods: This study enrolled a total of 55 COPD patients, 24 of which had AECOPD and 31 had stable COPD. All patients' basic demographic and clinical data were recorded and blood samples were collected. Results: Serum endocan levels were significantly higher in the AECOPD group compared to the stable COPD and control groups (for both p < 0.001) and stable COPD group had higher levels than the control group (p < 0.005). Additionally, serum endocan levels were negatively correlated with FVC, FEV1, partial oxygen pressure and oxygen saturation (r = -0.30, p = 0.03; r = -0.34, p = 0.01; r = -0.34, p = 0.01 and r = -0.36, p = 0.007 respectively), and positively correlated with disease duration and systolic pulmonary artery pressure (r = 0.47, p < 0.001; r = 0.31, p = 0.02 respectively). A cut-off value of 434.29 pg/ml for endocan predicted exacerbation with a sensitivity of 79% and a specificity of 84% (AUC: 0.778, 95% Cl 0.648-0.909; p < 0.001). Logistic regression analysis revealed that increased endocan levels was independent predictor of COPD exacerbation (OR = 9.32, 95%CI, 1.64-52.95; p = 0.01). Conclusion: Endocan may be a novel biomarker for detection of endothelial dysfunction and prediction of exacerbations in patients with COPD.en_US
dc.identifier.doi10.1111/crj.13320
dc.identifier.endpage453en_US
dc.identifier.issue4en_US
dc.identifier.startpage445en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12899/1201
dc.identifier.volume15en_US
dc.institutionauthorIn, Erdal
dc.language.isoenen_US
dc.publisherErdal İnen_US
dc.relation.ispartofClin Respir Jen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectchronic obstructive pulmonary disease;en_US
dc.subjectendocan;en_US
dc.subjectendothelial cell specific molecule-1;en_US
dc.subjectendothelial dysfunction;en_US
dc.subjectsystemic inflammationen_US
dc.titleEndocan as a potential biomarker of disease severity and exacerbations in COPDen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
crj.13320.pdf
Boyut:
15.12 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: